Pt
|
Age at death (yrs)
|
Sex
|
ApoE genotype
|
CERAD score
|
Thal phase
|
Braak AT8 stage
|
CAA score
|
Type
|
---|
1
|
79
|
male
|
3/4
|
C
|
5
|
5
|
2
|
AD
|
2
|
87
|
female
|
ND
|
C
|
5
|
5
|
1
|
AD
|
3
|
92
|
female
|
ND
|
B
|
5
|
5
|
0
|
AD
|
4
|
85
|
male
|
2/3
|
0
|
2
|
2
|
4
|
CAA
|
5
|
87
|
female
|
3/3
|
0
|
5
|
2
|
8
|
CAA
|
6
|
91
|
male
|
3/4
|
A
|
5
|
3
|
8
|
CAA
|
7
|
81
|
female
|
3/3
|
C
|
5
|
4
|
8
|
AD + CAA
|
8
|
89
|
male
|
3/3
|
B
|
5
|
5
|
8
|
AD + CAA
|
9
|
80
|
female
|
3/3
|
B
|
5
|
5
|
8
|
AD + CAA
|
10
|
89
|
female
|
3/3
|
C
|
5
|
5
|
8
|
AD + CAA
|
11
|
86
|
female
|
3/3
|
0
|
3
|
2
|
1
|
less Aβ
|
12
|
82
|
male
|
3/3
|
0
|
1
|
2
|
2
|
less Aβ
|
- Pt., patients; yrs, year; ApoE, apolipoprotein E; ND, not done; AD, Alzheimer’s disease; CAA, cerebral amyloid angiopathy; Aβ, amyloid β protein